Announcements Trials
Browse Landscape

Phase

Phase NA 11Phase 2 2Phase 3 1

Status

Completed 2Unknown 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Glioblastoma 1Camurati-Engelmann Syndrome 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Drug Delivery Systems × Clear all
NCT01369420 2016-11-08

NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer

Angiodynamics, Inc.

Phase 2 Completed
10 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00431561 2013-12-03

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Isarna Therapeutics GmbH

Phase 2 Completed
141 enrolled
CNS

Astrocytoma, Brain Neoplasms, Camurati-Engelmann Syndrome, Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡